Lambda Therapeutic Research Ltd. is a full service Contract Research Organization having headquartered in Ahmedabad, India and also have facilities and operations in Mumbai (India), Toronto (Canada), Warsaw (Poland), London (UK) and USA.
ï»¿ï»¿Lambda fully exploits potential of India to offer full spectrum of clinical trial services to pharmaceutical, biopharmaceutical and medical devices companies within timelines and stipulated cost while maintaining quality of clinical trial employing state-of-the-art technologies and more than 600 trained research professionals globally.
Lambda's gamut of services includes Early and Late Phase Clinical Development like Phase I, First-in-Man, BA/BE, Drug-Drug-Interaction studies as well as Phase II – IV clinical studies, Bioanalytical, Patient based PK studies, Clinical Data Management, Pharmacovigilance, Independent Imaging Review and Central Laboratory Services as a package or a stand-alone service.
Lambda has rich experience of conducting more than 4,500 clinical studies globally by applying innovative technologies, therapeutic expertise and a commitment to quality in order to help clients develop products safely, effectively and quickly.
Lambda has been inspected successfully at various times by DCGI (Indian Regulatory Agency), USFDA, ANVISA-Brazil, MHRA, Health Canada, AFSSAPS, PHSS, OGYI, AGES, Thai – MOH, CAP and WHO. Lambda has faced over 50 successful regulatory audits and inspections globally without any significant findings till date. Lambda was awarded as "Indian Clinical Research Company of the Year" at âThe Alexandria – Frost & Sullivan 2010 India Excellence in Healthcare Awards' for committed and innovative business strategies.
Lambda's commitment to deliver competitive, accurate and timely solutions can benefit drug development companies to make sound and cost effective decisions about their clinical trials.
Dr. Manish Sharma, Vice President, Lambda Therapeutic Research, India, will be sharing his views at Pharma Trials World Asia 2012 this March about "Optimising Clinical Trials in Asian Powerhouses"